Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a major Chinese research-driven pharmaceutical conglomerate that develops, manufactures, and markets chemical medicines and biologics. The company conducts business through primary medical categories including oncology, liver diseases, respiratory indications, surgery, and orthopedic treatments. Its principal revenue drivers consist of high-volume sales of prescription drugs, novel biopharmaceuticals, generic medicines, and active pharmaceutical ingredients to hospitals and healthcare providers. Sino Biopharmaceutical holds a leading market position as one of China's largest pharmaceutical companies, maintaining extensive commercialization networks and advanced research facilities across Mainland China. The enterprise focuses heavily on increasing R&D investments in innovative therapies, advancing clinical trials for targeted cancer drugs, acquiring international biopharmaceutical assets, and digitizing healthcare distribution. Sino Biopharmaceutical Limited is headquartered in Hong Kong, and its common shares are publicly listed and traded on the Hong Kong Stock Exchange.
21 of the funds FundTelligence covers report a position in Sino Biopharmaceutical.
- Legal name
- Sino Biopharmaceutical Ltd.
- Sector
- Health Care
- Country
- Hong Kong SAR China
- Funds holding it
- 21
Funds holding Sino Biopharmaceutical
- Handelsbanken Helse Tema — Handelsbanken · 0.47 % (full portfolio disclosed, October 2026)
- Indecap Guide Tillväxtmarknadsfond — Indecap · 0.44 % (full portfolio disclosed, June 2026)
- Handelsbanken Asia Tema — Handelsbanken · 0.29 % (full portfolio disclosed, August 2026)
- SEB Asienfond ex Japan — SEB · 0.29 % (full portfolio disclosed, June 2026)
- SEB Emerging Marketsfond — SEB · 0.15 % (full portfolio disclosed, June 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.08 % (full portfolio disclosed, December 2025)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.06 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 21 funds holding it.